The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.

Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib have a higher rate and greater magnitude of early tumour shrinkage compared to those treated with everolimus. This early tumour shrinkage is associated with prolonged overall survival.

Read more in Renal & Urology News here